Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine

Eli Lilly's investigational oral GLP-1 agonist, orforglipron, demonstrated significant efficacy in its Phase 3 ATTAIN-1 trial, achieving an average weight loss of 12.4% (27.3 lbs) at the highest dose over 72 weeks, alongside substantial improvements in cardiometabolic risk factors, including blood sugar normalization in up to 91% of prediabetic participants. While exhibiting a safety profile consistent with the GLP-1 class, marked by common gastrointestinal adverse events, these results position orforglipron as a potentially impactful oral treatment for obesity, with global regulatory submissions for obesity expected as early as next year, and for type 2 diabetes in 2026.

Analysis

Eli Lilly's investigational once-daily oral GLP-1, orforglipron, has demonstrated robust efficacy in its Phase 3 ATTAIN-1 trial, reinforcing the company's dominant position in the metabolic disease space. The study, published in The New England Journal of Medicine, met its primary endpoint with the highest dose (36 mg) delivering a mean weight loss of 12.4% (27.3 lbs) at 72 weeks, significantly superior to placebo. The data also highlights compelling secondary outcomes, with 39.6% of participants achieving at least 15% weight loss and up to 91% of prediabetic subjects normalizing their blood sugar levels. Beyond weight loss, the drug showed clinically meaningful improvements across key cardiometabolic risk factors, including reductions in non-HDL cholesterol, triglycerides (-21.6%), and systolic blood pressure (-6.7 mm Hg). The safety profile was consistent with the GLP-1 class, characterized by mild-to-moderate gastrointestinal events, though the treatment discontinuation rate due to adverse events reached 10.3% at the highest dose. The absence of a hepatic safety signal is a critical positive. With regulatory submissions for obesity planned as early as next year, orforglipron's oral formulation presents a significant commercial advantage of convenience over incumbent injectable treatments.

Key Decisions for Investors

• The strong efficacy and broad cardiometabolic benefits of orforglipron, coupled with its convenient oral administration, significantly strengthen Eli Lilly's pipeline and competitive positioning in the multi-billion dollar obesity market, supporting a continued bullish thesis on the stock.
• Investors should closely monitor the tolerability profile, particularly the 10.3% discontinuation rate at the highest dose due to gastrointestinal side effects, as this will be a key factor in physician adoption and commercial uptake versus competing therapies.
• The clear timeline for regulatory submissions for obesity in 2025 and type 2 diabetes in 2026 provides defined catalysts; any updates on these submissions or potential competitor data should be considered key events for portfolio adjustments.